Recent considerations in nonsteroidal anti-inflammatory drug gastropathy

American Journal of Medicine

Volumn 105, Issue 1 B, 1998, Pages 31S-38S

  Singh, Gurkirpal ^a,b  

^a STANFORD UNIVERSITY   (United States)

^b STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTACID AGENT; HISTAMINE H2 RECEPTOR ANTAGONIST; NONSTEROID ANTIINFLAMMATORY AGENT;

CONFERENCE PAPER; GASTROINTESTINAL DISEASE; HUMAN; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROSTAGLANDIN SYNTHESIS; RISK ASSESSMENT; STOMACH DISEASE; STOMACH ULCER; TREATMENT OUTCOME;

EID: 0032572548     PISSN: 00029343     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9343(98)00072-2     Document Type: Conference Paper

References (48)

1. Singh G, Ramey DR, Morfeld D, et al. Gastrointestinal tract complications of non-steroidal anti-inflammatory drug treatment in rheumatoid arthritis - A prospective observational cohort study. Arch Intern Med. 1996;156:1530-1536.
2. Fries JF, McShane DJ. ARAMIS (The American Rheumatism Association Medical Information System): a prototypical national chronic-disease data bank. West J Med. 1986; 145:798-804.
3. Fries JF, Ramey DR, Singh G, et al. A reevaluation of aspirin therapy in rheumatoid arthritis. Arch Intern Med. 1993;153: 2465-2471.
4. Singh G, Fries JF, Spitz PW, et al. Toxic effects of azathioprine in rheumatoid arthritis: a national post-marketing perspective. (Abstr.) Arthritis Rheum. 1989;32:837-843.
5. Singh G, Fries JF, Williams CA, et al. Toxicity profiles of disease modifying antirheumatic drugs in rheumatoid arthritis. J Rheumatol. 1991;18:188-194.
6. Fries JF, Spitz PW, Kraines RG, Holman HR. Measurement of patient outcome in arthritis. Arthritis Rheum. 1980;23: 137-145.
7. Ramey DR, Singh GS, Fries JF. The Health Assessment Questionnaire 1995: status and review. In: Spilker B, ed. Pharmacoeconomics and Quality of Life in Clinical Trials. 2nd ed. Philadelphia: Lippincott-Raven; 1996:227-237.
8. Buchanan WW, Brooks PM. Prediction of organ system toxicity with anti-rheumatic drug therapy. In: Bellamy N, ed. Prognosis in the Rheumatic Diseases. Boston: Kluwer Academic Publishers; 1991:403-450.
9. Brooks PM, Day RO. Nonsteroidal antiinflammatory drugs - differences and similarities. N Engl J Med. 1991; 324:1716-1725.
10. Hardin JG, Longenecker GL Handbook of Drug Therapy in Rheumatic Disease. Pharmacology and Clinical Aspects. Boston: Little, Brown and Company. 1992.
11. Paulus HE. Nonsteroidal Anti-inflammatory Drugs. In: Kelly WN, Harris ED Jr, Ruddy S, Sledge CB, eds. Textbook of Rheumatology. Philadelphia: WB Saunders Company; 1989:765-791.
12. Ehsanullah RS, Page MC, Tildesley G, Wood JR. Prevention of gastroduodenal damage induced by non-steroidal anti-inflammatory drugs: controlled trial of ranitidine. BMJ. 1988;297:1017-1021.
13. Caruso I, Bianchi Porro G. Gastroscopic evaluation of antiinflammatory agents. BMJ. 1980;280:75-78.
14. McCarthy DM. Nonsteroidal antiinflammatory drug induced ulcers: management by traditional therapies. Gastroenterology. 1989;96:662-674.
15. Gabriel SE, Jaakkimainen L, Bombardier C. The cost-effectiveness of misoprostol for nonsteroidal antiinflammatory drug-associated adverse gastrointestinal events. Arthritis Rheum. 1993;36:447-459.
16. Gabriel SE, Jaakkimainen L, Bombardier C. Risk for serious gastrointestinal complications related to use of nonsteroidal anti-inflammatory drugs. A meta-analysis. Ann Intern Med. 1991;115:787-796.
17. Paulus HE. Government affairs. FDA Arthritis Advisory Committee meeting: risks of agranulocytosis/aplastic anemia, flank pain, and adverse gastrointestinal effects with the use of nonsteroidal antiinflammatory drugs. Arthritis Rheum. 1987;30:593-595.
18. Silverstein FE, Graham DY, Senior JR, et al. Misoprostol reduces serious gastrointestinal complications in patients with rheumatoid arthritis receiving nonsteroidal anti-inflammatory drugs. A randomized, double-blind, placebo-controlled trial. Ann Intern Med. 1995;123:241-249.
19. Langman MJ, Weil J, Wainwright P, et al. Risks of bleeding peptic ulcer associated with individual non-steroidal anti-inflammatory drugs. Lancet. 1994;343:1075-1078.
20. Garcia Rodriguez LA, Jick H. Risk of upper gastrointestinal bleeding and perforation associated with individual nonsteroidal anti-inflammatory drugs. Lancet. 1994;343:769-772.
21. Singh G, Ramey DR, Terry R, Triadafilopoulus G. NSAID-related effects on the GI tract: an ever widening spectrum. (Abstr.) Gastroenterology. 1997;112:A42.
22. Griffin MR, Piper JM, Daugherty JR, et al. Nonsteroidal anti-inflammatory drug use and increased risk for peptic ulcer disease in elderly persons. Ann Intern Med. 1991;114: 257-263.
23. Armstrong CP, Blower AL Non-steroidal anti-inflammatory drugs and life threatening complications of peptic ulcerations. Gut. 1987;28:527-532.
24. National Center for Health Statistics. GMWKI: total deaths for each cause by 5-year age groups, United States, 1994 (unpublished data from NCHS website data warehouse). Hyattsville, MD: Public Health Service, 1997.
25. Larkai EN, Smith JL, Lidsky MD. Gastroduodenal mucosa and dyspeptic symptoms in arthritis patients during chronic nonsteroidal anti-inflammatory drug use. Am J Gastroenterol. 1987;82:1153-1158.
26. Polisson R. Nonsteroidal anti-inflammatory drugs: practical and theoretical considerations in their selection. Am J Med. 1996;100(suppl 2A):31S-36S.
27. Lichtenstein DR, Syngal S, Wolfe MM. Nonsteroidal antiinflammatory drugs and the gastrointestinal tract. The double-edged sword. Arthritis Rheum. 1995;38:5-18.
28. Bjorkman DJ. Nonsteroidal anti-inflammatory drug-induced gastrointestinal injury. Am J Med. 1996;101(suppl 1A):25S-32S.
29. Longstreth GF. Epidemiology of hospitalization for acute upper gastrointestinal hemorrhage: a population-based study. Am J Gastroenterol. 1995;90:206-210.
30. Greene JM, Winickoff RN. Cost-conscious prescribing of nonsteroidal anti-inflammatory drugs for adults with arthritis. A review and suggestions. Arch Intern Med. 1992;152: 1995-2002.
31. Hallas J, Lauritsen J, Villadsen HD, Gram LF. Nonsteroidal anti-inflammatory drugs and upper gastrointestinal bleeding, identifying high-risk groups by excess risk estimates. Scand J Gastroenterol. 1995;30:438-444.
32. Hochain P, Berkelmans I, Czernichow P, et al. Which patients taking non-aspirin nonsteroidal anti-inflammatory drugs bleed? A case-control study. Eur J Gastroenterol Hepatol. 1995;7:419-426.
33. Piper JM, Ray WA, Daugherty JR, et al. Corticosteroid use and peptic ulcer disease: role of nonsteroidal anti-inflammatory drugs. Ann Intern Med. 1991;114:735-740.
34. Shorr RI, Ray WA, Daugherty JR, et al. Concurrent use of non-steroidal anti-inflammatory drugs and oral anticoagulants places elderly persons at high risk for hemorrhagic peptic ulcer disease. Arch Intern Med. 1993;153:1665-1670.
35. Lanza FL, Royer GL, Nelson RS, et al. A comparative endoscopic evaluation of damaging effects of nonsteroidal antiinflammatory agents on the gastric and duodenal mucosa. Am J Gastroenterol. 1981;75:17-21.
36. Lanza FL, Nelson RS, Greenberg BP. Effects of fenbufen, indomethacin, naproxen and placebo on gastric mucosa of normal volunteers. Am J Med. 1983;75:75-79.
37. Lanza FL. Endoscopic studies of gastric and duodenal injury after the use of ibuprofen, aspirin, and other nonsteroidal antiinflammatory drugs. Am J Med. 1984;77(suppl 1a): 19-24.
38. Lanza F, Rack MF, Lyn M, et al. An endoscopic comparison of the effects of etodolac, indomethacin, ibuprofen, naproxen, and placebo on the gastrointestinal mucosa. J Rheumatol. 1987;14:338-341.
39. Lanza F, Rack MF, Doucette M, et al. An endoscopic comparison of the gastroduodenal injury seen with salsalate and naproxen. J Rheumatol. 1989;16:1570-1574.
40. Carson JL, Strom BL, Morse ML, et al. The relative gastrointestinal toxicity of the nonsteroidal anti-inflammatory drugs. Arch Intern Med. 1987;147:1054-1059.
41. Fries JF, Spitz PW, Williams CA, et al. A toxicity index for comparison of side effects among different drugs. Arthritis Rheum. 1990;33:121-130.
42. Fries JF, Williams CA, Block DA. The relative toxicity of non-steroidal anti-inflammatory drugs. Arthritis Rheum. 1991;34:1353-1360.
43. Fries JF, Williams CA, Ramey D, Bloch DA. The relative toxicity of disease modifying antirheumatic drugs (DMARDs). Arthritis Rheum. 1993;36:297-306.
44. Singh G, Williams CA, Ramey Dr, Fries JF. A toxicity index for comparison of gastrointestinal toxicity of non-steroidal anti-inflammatory drugs (NSAIDs). (Abstr.) Arthritis Rheum. 1993;36(suppl 9):S178.
45. Singh G, Ramey Dr, Morfeld D, Fries JF. Comparative toxicity of non-steroidal anti-inflammatory agents. Pharmacol Ther. 1994;62:1750-1791.
46. Robinson MG, Griffin JW Jr, Bowers J, et al. Effect of ranitidine on gastroduodenal mucosal damage induced by nonsteroidal anti-inflammatory drugs. Dig Dis Sci. 1989;34: 424-428.
47. Oddsson E, Gudjonsson H, Thjodleifsson B. Comparison between ranitidine and omeprazole for protection against gastroduodenal damage caused by naproxen. Scand J Gastroenterol. 1992;27:1045-1048.
48. Avorn J, Solomon D, Levin R, Lo J. Epidemiologic analysis of prophylactic drug use and NSAID gastropathy. (Abstr.) Arthritis Rheum. 1996;39(suppl):S165.